NORS2791 product candidate will be a topical formulation of NORSTM for the treatment of onychomycosis, a fungal infection of the toenail. For these patients, NORSTM will be delivered via a specially designed bandage containing a NO releasing gel.
Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and eventually separated from the nail bed. Pain, discomfort, and disfigurement may precipitate serious physical and occupational limitations for the patient. The fungus, Trichophyton rubrum, is the most common dermatophyte involved in onychomycosis.
NORSTM has been shown to be highly effective in eradicating T. rubrum, both in-vitro and in a human proof of concept trial. Additionally, it is expected to act as an anti-inflammatory, reducing associated symptoms throughout the course of treatment.
The US onychomycosis market has been assessed as a steadily growing market. Given that an estimated 35 million Americans will develop the infection, a high demand for treatment alternatives is anticipated. The market is expected to reach $5 billion by 2021, and some generic topical agents have achieved $125 million in peak US sales.